Gonadotropin-releasing hormone and its receptor in normal and malignant cells

Endocrine-Related Cancer

Volumn 11, Issue 4, 2004, Pages 725-748

  Harrison, G S ^a   Wierman, M E ^a,b   Nett, T M ^c   Glode, L M ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; CETRORELIX; CYPROTERONE; DESLORELIN; DIETHYLSTILBESTROL; FLUTAMIDE; FOLLITROPIN; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN ASSOCIATED PEPTIDE; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADOTROPIN; GOSERELIN; HISTRELIN; ITURELIX; LEUPRORELIN; LUTEINIZING HORMONE; MEGESTROL; NAFARELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE; TEVERELIX; TRIPTORELIN; UNINDEXED DRUG;

ADENOHYPOPHYSIS; BREAST CANCER; CANCER CELL; CANCER CONTROL; CASTRATION; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TARGETING; ENDOMETRIOSIS; FOLLITROPIN RELEASE; GAMETOGENESIS; GONADORELIN RELEASE; GONADOTROPIN RELEASE; GYNECOMASTIA; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; HYPOTENSION; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LEIOMYOMA; LUTEINIZING HORMONE RELEASE; MITOSIS INHIBITION; MOLECULAR INTERACTION; NAUSEA AND VOMITING; NONHUMAN; OVARY CANCER; PRECOCIOUS PUBERTY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PULSATILE HORMONE RELEASE; REGULATORY MECHANISM; REPRODUCTION; REVIEW; SIGNAL TRANSDUCTION; SYNCOPE; THROMBOEMBOLISM;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYPOTHALAMUS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PITUITARY GLAND, ANTERIOR; RECEPTORS, LHRH; SIGNAL TRANSDUCTION;

EID: 11244260381     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00777     Document Type: Review

References (166)

1. Abou-Jawde R, Choueiri T, Alemany C & Mekhail T 2003 An overview of targeted treatments in cancer. Clinical Therapeutics 25 2121-2137.
2. Albertsen PC, Fryback DG, Storer BE, Kolon TF & Fine J 1995 Long-term survival among men with conservatively treated localized prostate cancer. Journal of the American Medical Association 274 626-631.
3. Allen TM 2002 Ligand-targeted therapeutics in anticancer therapy. Nature Reviews of Cancer 2 750-763.
4. Anonymous 1984 Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. New England Journal of Medicine 311 1281-1286.
5. Anonymous 1996 Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 348 1189-1196.
6. Anonymous 2000 Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355 1491-1498.
7. Anonymous 2003 Urologists face major cut in AWP of cancer drugs. Urology Times (1 December).
8. Avila DM, Zoppi S & McPhaul MJ 2001 The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 76 135-142.
9. Bahk JY, Hyun JS, Chung SH, Lee H, Kim MO, Lee BH & Choi WS 1995 Stage specific identification of the expression of GnRH mRNA and localization of the GnRH receptor in mature rat and adult human testis. Journal of Urology 154 1958-1961.
10. Barbieri RL 1998 Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment. Journal of Reproductive Medicine 43 287-292.
11. Bast R, Zalutsky M & Frankel A 1996 Monoclonal serotherapy. In Cancer Medicine, Edn 4 pp 1245-1262. Eds J Holland, E Frei, R Bast, D Morton, D Kufe & R Weichselbaum. Baltimore: Williams and Wilkins.
12. Bedecarrats GY & Kaiser UB 2003 Differential regulation of gonadotropin subunit gene promoter activity by pulsatile gonadotropin-releasing hormone (GnRH) in perifused L beta T2 cells: role of GnRH receptor concentration. Endocrinology 144 1802-1811.
13. Ben-Yehudah A, Yarkoni S, Nechushtan A, Belostotsky R & Lorberboum-Galski H 1999 Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice. Medical Oncology 16 38-45.
14. Boccardo F, Blamey R, Klijn JG, Tominaga T, Duchateau L & Sylvester R 1999 LHRH-Agonist (LHRH-A) + tamoxifen (TAM) versus LHRH-A alone in premenopausal women with advanced breast cancer (ABC): results of a meta-analysis of four trials. Proceedings of the American Society of Clinical Oncology 18 110a (Abstract).
15. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T et al. 1997 Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New England Journal of Medicine 337 295-300.
16. Bono AV, Salvadore M & Celato N 2002 Gonadotropin-releasing hormone receptors in prostate tissue. Analytical and Quantitative Cytology and Histology 24 221-227.
17. Borroni R, Di Blasio AM, Gaffuri B, Santorsola R, Busacca M, Vigano P & Vignali M 2000 Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Molecular and Cellular Endocrinology 159 37-43.
18. Botte MC, Chamagne AM, Carre MC, Counis R & Kottler ML 1998 Fetal expression of GnRH and GnRH receptor genes in rat testis and ovary. Journal of Endocrinology 159 179-189.
19. Botte MC, Lerrant Y, Lozach A, Berault A, Counis R & Kottler ML 1999 LH down-regulates gonadotropin-releasing hormone (GnRH) receptor, but not GnRH, mRNA levels in the rat testis. Journal of Endocrinology 162 409-415.
20. Brinkraann U & Pastan I 1994 Immunotoxins against cancer. Biochimica et Biophysica Acta 1198 27-45.
21. Buzdar AU 2004 Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003. Clinical Cancer Research 10 355S-361S.
22. Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M & Gelber RD 2003 Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. Journal of the National Cancer Institute 95 1833-1846.
23. Chatzaki E, Bax CM, Eidne KA, Anderson L, Grudzinskas JG & Gallagher CJ 1996 The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor. Cancer Research 56 2059-2065.
24. Chen A, Ganor Y, Rahimipour S, Ben-Aroya N, Koch Y & Levite M 2002 The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs. Nature Medicine 8 1421-1426.
25. Cheng CK, Yeung CM, Chow BK & Leung PC 2002 Characterization of a new upstream GnRH receptor promoter in human ovarian granulosa-luteal cells. Molecular Endocrinology 16 1552-1564.
26. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M & Smith JA 1991 Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. Journal of the American Medical Association 265 618-621.
27. Chon JK, Jacobs SC & Naslund MJ 2000 The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer. Journal of Urology 164 735-737.
28. Chou CS, MacCalman CD & Leung PC 2003a Differential effects of gonadotropin-releasing hormone I and II on the urokinase-type plasminogen activator/plasminogen activator inhibitor system in human decidual stromal cells in vitro. Journal of Clinical Endocrinology and Metabolism 88 3806-3815.
29. Chou CS, Tai CJ, MacCalman CD & Leung PC 2003b Dose-dependent effects of gonadotropin releasing hormone on matrix metalloproteinase (MMP)-2, and MMP-9 and tissue specific inhibitor of metalloproteinases-1 messenger ribonucleic acid levels in human decidual stromal cells in vitro. Journal of Clinical Endocrinology and Metabolism 88 680-688.
30. Chou CS, Zhu H, MacCalman CD & Leung PC 2003c Regulatory effects of gonadotropin-releasing hormone (GnRH) I and GnRH II on the levels of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of metalloproteinases-1 in primary cultures of human extravillous cytotrophoblasts. Journal of Clinical Endocrinology and Metabolism 88 4781-4790.
31. Clayton RN & Catt KJ 1981 Gonadotropin-releasing hormone receptors: characterization, physiological regulation, and relationship to reproductive function. Endocrine Reviews 2 186-209.
32. Collier RJ & Kaplan DA 1984 Immunotoxins. Scientific American 251 56-64.
33. Crawford ED 2003 Early versus late hormonal therapy: debating the issues. Urology 61 8-13.
34. Crump M, Sawka CA, DeBoer G, Buchanan RB, Ingle JN, Forbes J, Meakin JW, Shelley W & Pritchard KI 1997 An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Research and Treatment 44 201-210.
35. Davidson L, Pawson AJ, Millar RP & Maudsley S 2004 Cytoskeletal reorganization dependence of signaling by the gonadotropin-releasing hormone receptor. Journal of Biological Chemistry 279 1980-1993.
36. Densmore VS & Urbanski HF 2003 Relative effect of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on gonadotropin release. Journal of Clinical Endocrinology and Metabolism 88 2126-2134.
37. Dufau ML, Warren DW, Knox GF, Loumaye E, Castellon ML, Luna S & Catt KJ 1984 Receptors and inhibitory actions of gonadotropin-releasing hormone in the fetal Leydig cell. Journal of Biological Chemistry 259 2896-2899.
38. Ellsworth BS, White BR, Burns AT, Cherrington BD, Otis AM & Clay CM 2003a c-Jun N-terminal kinase activation of activator protein-1 underlies homologous regulation of the gonadotropin-releasing hormone receptor gene in alpha T3-1 cells. Endocrinology 144 839-849.
39. Ellsworth BS, Burns AT, Escudero KW, Duval DL, Nelson SE & Clay CM 2003b The gonadotropin releasing hormone (GnRH) receptor activating sequence (GRAS) is a composite regulatory element that interacts with multiple classes of transcription factors including Smads, AP-1 and a forkhead DNA binding protein. Molecular and Cellular Endocrinology 206 93-111.
40. Emons G & Schally AV 1994 The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Human Reproduction 9 1364-1379.
41. Emons G, Schroder B, Ortmann O, Westphalen S, Schulz KD & Schally AV 1993 High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. Journal of Clinical Endocrinology and Metabolism 77 1458-1464.
42. Emons G, Ortmann O, Teichert HM, Fassl H, Lohrs U, Kuliander S, Kauppila A, Ayalon D, Schally A & Oberheuser F 1996 Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer 78 1452-1460.
43. Emons G, Weiss S, Ortmann O, Grundker C & Schulz KD 2000 LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. European Journal of Endocrinology 142 665-670.
44. Emons G, Grundker C, Gunthert AR, Westphalen S, Kavanagh J & Verschraegen C 2003 GnRH antagonists in the treatment of gynecological and breast cancers. Endocrine-Related Cancer 10 291-299.
45. Faure N, Labrie F, Lemay A, Belanger A, Gourdeau Y, Laroche B & Robert G 1982 Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men. Fertility and Sterility 37 416-424.
46. Fortune JE, Sirois J, Turzillo AM & Lavoir M 1991 Follicle selection in domestic ruminants. Journal of Reproduction and Fertility 43 (Suppl) 187-198.
47. Frankel AE, Kreitman RJ & Sausville EA 2000 Targeted toxins. Clinical Cancer Research 6 326-334.
48. Friess H, Buchler M, Kiesel L, Kruger M & Beger HG 1991 LH-RH receptors in the human pancreas. Basis for antihormonal treatment in ductal carcinoma of the pancreas. International Journal of Pancreatology 10 151-159.
49. Gault PM, Maudsley S & Lincoln GA 2003 Evidence that gonadotropin-releasing hormone II is not a physiological regulator of gonadotropin secretion in mammals. Journal of Neuroendocrinology 15 831-839.
50. Goldenberg SL, Cleave ME, Taylor D & Bruchovsky N 1999 Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years' follow-up. Molecular Urology 3 287-292.
51. Granger A, Ngo-Muller V, Bleux C, Guigon C, Pincas H, Magre S, Daegelen D, Tixier-Vidal A, Counis R & Laverriere JN 2004 The promoter of the rat gonadotropin-releasing hormone receptor gene directs the expression of the human placental alkaline phosphatase reporter gene in gonadotrope cells in the anterior pituitary gland as well as in multiple extrapituitary tissues. Endocrinology 145 983-993.
52. van Groeninghen JC, Kiesel L, Winkler D & Zwirner M 1998 Effects of luteinising-hormone-releasing hormone on nervous-system tumours. Lancet 352 372-373.
53. Grundker C, Volker P, Schulz KD & Emons G 2000a Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Gynecologic Oncology 78 194-202.
54. Grundker C, Schulz K, Gunthert AR & Emons G 2000b Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells. Journal of Clinical Endocrinology and Metabolism 85 3815-3820.
55. Grundker C, Volker P & Emons G 2001 Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology 142 2369-2380.
56. Grundker C, Gunthert AR, Millar RP & Emons G 2002a Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-H on tumor cell proliferation. Journal of Clinical Endocrinology and Metabolism 87 1427-1430.
57. Grundker C, Gunthert AR, Westphalen S & Emons G 2002b Biology of the gonadotropin-releasing hormone system in gynecological cancers. European Journal of Endocrinology 146 1-14.
58. Guillemin R 1967 The adenohypophysis and its hypothalamic control. Annual Review of Physiology 29 313-348.
59. Gunther R, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE & Uckun FM 1993 In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/ lymphoma in mice with severe combined immunodeficiency. Leukemia 7 298-309.
60. de Haes H, Olschewski M, Kaufmann M, Schumacher M, Jonat W & Sauerbrei W 2003 Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. Journal of Clinical Oncology 21 4510-4516.
61. Halmos G, Arencibia JM, Schally AV, Davis R & Bostwick DG 2000 High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. Journal of Urology 163 623-629.
62. Higano CS 2003 Side effects of androgen deprivation therapy, monitoring and minimizing toxicity. Urology 61 32-38.
63. Hoffken K 1992 LH-RH agonists in the treatment of premenopausal patients with advanced breast cancer. Recent Results in Cancer Research 124 91-104.
64. Huirne JA & Lambalk CB 2001 Gonadotropin-releasing-hormone-receptor antagonists. Lancet 358 1793-1803.
65. Imai A & Tamaya T 2000 GnRH receptor and apoptotic signaling. Vitamins and Hormones 59 1-33.
66. Imai A, Ohno T, Iida K, Fuseya T, Furui T & Tamaya T 1994 Gonadotropin-releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types. Cancer 74 2555-2561.
67. Jacobs E, Watson SA, Michaeli D, Ellis IO & Robertson JF 1999 Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts. British Journal of Cancer 80 352-359.
68. Johnson L & Thompson DL Jr 1983 Age-related and seasonal variation in the Sertoli cell population, daily sperm production and serum concentrations of follicle-stimulating hormone, luteinizing hormone and testosterone in stallions. Biology of Reproduction 29 777-789.
69. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A et al. 2002 Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. Journal of Clinical Oncology 20 4628-4635.
70. Kakar SS & Jennes L 1995 Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues. Cancer Letters 98 57-62.
71. Kakar SS, Grizzle WE & Neill JD 1994 The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Molecular and Cellular Endocrinology 106 145-149.
72. Kang SK, Cheng KW, Ngan ES, Chow BK, Choi KC & Leung PC 2000 Differential expression of human gonadotropin-releasing hormone receptor gene in pituitary and ovarian cells. Molecular and Cellular Endocrinology 162 157-166.
73. Kang SK, Choi KC, Yang HS & Leung PC 2003 Potential role of gonadotrophin-releasing hormone (GnRH)-I and GnRH-II in the ovary and ovarian cancer. Endocrine-Related Cancer 10 169-177.
74. Karten MJ & Rivier JE 1986 Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocrine Reviews 7 44-66.
75. Keeney DS, Sprando RL, Robaire B, Zirkin BR & Ewing LL 1990 Reversal of long-term LH deprivation on testosterone secretion and Leydig cell volume, number and proliferation in adult rats. Journal of Endocrinology 127 47-58.
76. Kottler ML, Starzec A, Carre MC, Lagarde JP, Martin A & Counis R 1997 The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer. International Journal of Cancer 71 595-599.
77. Kovacs M, Serially AV, Nagy A, Koppan M & Groot K 1997 Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. PNAS 94 1420-1425.
78. Kraus S, Naor Z & Seger R 2001 Intracellular signaling pathways mediated by the gonadotropin-releasing hormone (GnRH) receptor. Archives of Medical Research 32 499-509.
79. Krsmanovic LZ, Mores N, Navarro CE, Arora KK & Catt KJ 2003 An agonist-induced switch in G protein coupling of the gonadotropin-releasing hormone receptor regulates pulsatile neuropeptide secretion. PNAS 100 2969-2974.
80. Kühn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM, Dahan R et al. 1989 Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). New England Journal of Medicine 321 413-418.
81. Labrie F 1991 Endocrine therapy for prostate cancer. Endocrinology and Metabolism Clinics of North America 20 845-872.
82. Labrie F 2004 Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. Journal of Andrology 25 305-313.
83. Labrie F, Belanger A, Cusan L, Seguin C, Pelletier G, Kelly PA, Reeves JJ, Lefebure FA, Lemay A & Ranaud JP 1980 Antifertility effects of LHRH agonists in the male. Journal of Andrology 1 209-228.
84. Labrie F, Belanger A, Kelly PA, Seguin C, Cusan L, Lefebvre FA, Reeves JJ, Lemay A, Faure N, Gourdeau Y et al. 1981 Antifertility effects of luteinizing hormone-releasing hormone (LHRH) agonists. Progress in Clinical and Biological Research 74 273-291.
85. Labrie F, Dupont A, Belanger A, Emond J & Monfette G 1984 Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. PNAS 81 3861-3863.
86. Labrie F, Dupont A, Belanger A & Lachance R 1987 Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. Journal of Urology 138 804-806.
87. Labrie F, Belanger A, Dupont A, Luu-The V, Simard J & Labrie C 1993 Science behind total androgen blockade: from gene to combination therapy. Clinical and Investigative Medicine 16 475-492.
88. Labrie F, Belanger A, Cusan L, Simard J, Luu-The V, Labrie C, Gomez JL, Diamond P & Candas B 1996 History of LHRH agonist and combination therapy in prostate cancer. Endocrine-Related Cancer 3 243-278.
89. Labrie F, Candas B, Gomez JL & Cusan L 2002 Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 60 115-119.
90. Lee CY, Ho J, Chow SN, Yasojima K, Schwab C & McGeer PL 2000 Immunoidentification of gonadotropin releasing hormone receptor in human sperm, pituitary and cancer cells. American Journal of Reproductive Immunology 44 170-177.
91. Letsch M, Serially AV, Szepeshazi K, Halmos G & Nagy A 2003 Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clinical Cancer Research 9 4505-4513.
92. Limonta P, Moretti RM, Marelli MM & Motta M 2003 The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Frontiers in Neuroendocrinology 24 279-295.
93. Liu F, Usui I, Evans LG, Austin DA, Mellon PL, Olefsky JM & Webster NJ 2002 Involvement of both G(q/11) and G(s) proteins in gonadotropin-releasing hormone receptor-mediated signaling in L beta T2 cells. Journal of Biological Chemistry 277 32099-32108.
94. Liu F, Austin DA & Webster NJ 2003 Gonadotropin-releasing hormone-desensitized LbetaT2 gonadotrope cells are refractory to acute protein kinase C, cyclic AMP, and calcium-dependent signaling. Endocrinology 144 4354-4365.
95. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ et al. 2004 American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. Journal of Clinical Oncology 22 2927-2941.
96. van Loenen AC, Huirne JA, Schats R, Hompes PG & Lambalk CB 2002 GnRH agonists, antagonists, and assisted conception. Seminars in Reproductive Medicine 20 349-364.
97. Love RR & Philips J 2002 Oophorectomy for breast cancer: history revisited. Journal of the National Cancer Institute 94 1433-1434.
98. McArdle CA, Franklin J, Green L & Hislop JN 2002 Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors. Journal of Endocrinology 173 1-11.
99. MacColl G, Quinton R & Bouloux PM 2002 GnRH neuronal development: insights into hypogonadotrophic hypogonadism. Trends in Endocrinology and Metabolism 13 112-118.
100. McCue JM, Quirk CC, Nelson SE, Bowen RA & Clay CM 1997 Expression of a murine gonadotropin-releasing hormone receptor-luciferase fusion gene in transgenic mice is diminished by immunoneutralization of gonadotropin-releasing hormone. Endocrinology 138 3154-3160.
101. Marcil J, Ravindranath N & Sairam MR 1993 Cytotoxic activity of lutropin-gelonin conjugate in mouse Leydig tumor cells: potentiation of the hormonotoxin activity by different drugs. Molecular and Cellular Endocrinology 92 83-90.
102. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED & Trump D 1999 Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New England Journal of Medicine 341 1781-1788.
103. Miles LE, Hanyaloglu AC, Dromey JR, Pfleger KD & Eidne KA 2004 Gonadotropin-releasing hormone receptor-mediated growth suppression of immortalized LbetaT2 gonadotrope and stable HEK293 cell lines. Endocrinology 145 194-204.
104. Miller WR, Scott WN, Morris R, Fraser HM & Sharpe RM 1985 Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313 231-233.
105. Millikan R & Logothetics C 1997 National Comprehensive Cancer Network (NCC) Practice Guidelines version 1.97. Oncology 11 180-201.
106. Myers DA & Villemez CL 1989 A superactive hormonotoxin prepared with truncated diphtheria toxin. Biochemical and Biophysical Research Communications 163 161-164.
107. Nechushtan A, Yarkoni S, Marianovsky I & Lorberboum-Galski H 1997 Adenocarcinoma cells are targeted by the new GnRH-PE66 chimeric toxin through specific gonadotropin-releasing hormone binding sites. Journal of Biological Chemistry 272 11597-11603.
108. Neill JD 2002 GnRH and GnRH receptor genes in the human genome. Endocrinology 143 737-743.
109. Nichols J, Foss F, Kuzel TM, LeMaistre CF, Platanias L, Ratain MJ, Rook A, Saleh M & Schwartz G 1997 Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. European Journal of Cancer 33 (Suppl 1) S34-S36.
110. Nicholson RI & Walker KJ 1989 Gn-RH agonists in breast and gynaecologic cancer treatment. Journal of Steroid Biochemistry 33 801-804.
111. Noci I, Coronnello M, Borri P, Borrani E, Giachi M, Chieffi O, Marchionni M, Paglierani M, Buccoliero AM, Cherubini A et al. 2000 Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro. Cancer Letters 150 71-78.
112. Norwitz ER, Xu S, Jeong KH, Bedecarrats GY, Winebrenner LD, Chin WW & Kaiser UB 2002a Activin A augments GnRH-mediated transcriptional activation of the mouse GnRH receptor gene. Endocrinology 143 985-997.
113. Norwitz ER, Xu S, Xu J, Spiryda LB, Park JS, Jeong KH, McGee EA & Kaiser UB 2002b Direct binding of AP-1 (Fos/ Jun) proteins to a SMAD binding element facilitates both gonadotropin-releasing hormone (GnRH)- and activin-mediated transcriptional activation of the mouse GnRH receptor gene. Journal of Biological Chemistry 277 37469-37478.
114. Oefelein MG & Resnick MI 2003 Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 62 207-213.
115. Oefelein MG, Ricchiuti VS, Conrad PW, Goldman H, Bodner D, Resnick MI & Seftel A 2002 Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era. Urology 60 120-124.
116. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P et al. 2001 Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology 19 376-388.
117. Ortmann O & Diedrich K 1999 Pituitary and extrapituitary actions of gonadotrophin-releasing hormone and its analogues. Human Reproduction 14 (Suppl 1) 194-206.
118. Pai LH, Batra JK, FitzGerald DJ, Willingham MC & Pastan I 1992 Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys. Cancer Research 52 3189-3193.
119. Pater JL & Parulekar WR 2003 Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer - another step forward. Journal of the National Cancer Institute 95 1811-1812.
120. Pawson AJ, Morgan K, Maudsley SR & Millar RP 2003 Type II gonadotrophin-releasing hormone (GnRH-II) in reproductive biology. Reproduction 126 271-278.
121. Pether M, Goldenberg SL, Bhagirath K & Gleave M 2003 Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Canadian Journal of Urology 10 1809-1814.
122. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P et al. 1995 Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45 616-623.
123. Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H & Crowley WF Jr 2002 Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism 87 4128-4136.
124. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD & Walsh PC 1999 Natural history of progression after PSA elevation following radical prostatectomy. Journal of the American Medical Association 281 1591-1597.
125. Pritchard KI 2000 Current and future directions in medical therapy for breast carcinoma: endocrine treatment. Cancer 88 3065-3072.
126. Pritchard KI 2002 Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift? Journal of Clinical Oncology 20 4611-4614.
127. Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA & Glode LM 2003 GnRH-PAP hormonotoxin targets cytotoxicity to prostate cancer cell lines. Urology Research 31 374-377.
128. Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA, Crawford ED & Glode LM 2004 Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor. Cancer Research 64 2090-2095.
129. Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, Antolak SJ Jr & Pisansky TM 1999 Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. Journal of Urology 162 98-102.
130. Roelle S, Grosse R, Aigner A, Krell HW, Czubayko F & Gudermann T 2003 Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone. Journal of Biological Chemistry 278 47307-47318.
131. Ruf F, Fink MY & Sealfon SC 2003 Structure of the GnRH receptor-stimulated signaling network: insights from genomics. Frontiers in Neuroendocrinology 24 181-199.
132. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, Imbriaco M, Horak I, Conolly M, Ding C et al. 1999 Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. Journal of Clinical Oncology 17 948-957.
133. Sabeur K, Ball BA, Nett TM, Ball HH & Liu IK 2003 Effect of GnRH conjugated to pokeweed antiviral protein on reproductive function in adult male dogs. Reproduction 125 801-806.
134. Sadie H, Styger G & Hapgood J 2003 Expression of the mouse gonadotropin-releasing hormone receptor gene in alpha T3-1 gonadotrope cells is stimulated by cyclic 3′,5′-adenosine monophosphate and protein kinase A, and is modulated by Steroidogenic factor-1 and Nur77. Endocrinology 144 1958-1971.
135. Samdal F, Vada K, Lundmo PI & Mjolnerod OK 1991 Orchidectomy or LHRH-analogue? Which do the patients prefer and what treatment would Norwegian urologists prefer if they had advanced cancer of the prostate? Scandinavian Journal of Urology and Nephrology 25 197-199.
136. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH & Sullivan LD 1996 Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. Journal of Steroid Biochemistry and Molecular Biology 58 139-146.
137. Schlick J, Dulieu P, Desvoyes B, Adami P, Radom J & Jouvenot M 2000 Cytotoxic activity of a recombinant GnRH-PAP fusion toxin on human tumor cell lines. FEBS Letters 472 241-246.
138. Schwartz J & Vale W 1988 Dissociation of the adrenocorticotropin secretory responses to corticotropin-releasing factor (CRF) and vasopressin or oxytocin by using a specific cytotoxic analog of CRF. Endocrinology 122 1695-1700.
139. Schwartz J, Penke B, Rivier J & Vale W 1987 A new cytotoxin specific for the target cells of corticotropin-releasing factor. Endocrinology 121 1454-1460.
140. Shah BH, Farshori MP, Jambusaria A & Catt KJ 2003 Roles of Src and epidermal growth factor receptor transactivation in transient and sustained ERK1/2 responses to gonadotropin-releasing hormone receptor activation. Journal of Biological Chemistry 278 19118-19126.
141. Simms MS, Scholfield DP, Jacobs E, Michaeli D, Broome P, Humphreys JE & Bishop MC 2000 Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. British Journal of Cancer 83 443-446.
142. Singh V & Curtiss R 3rd 1991 Hormonotoxins: abrogation of ribosome inactivating property of gelonin in the disulfide linked ovine luteinizing hormone-gelonin conjugates. Biochemistry International 25 531-536.
143. Singh V & Curtiss R 3rd 1994 Hormonotoxins: the role of positive charge of lysine residue on the immunological, biological and cytotoxic properties of ovine lutropin-S-S-gelonin conjugates. Molecular and Cellular Biochemistry 130 91-101.
144. Smith MR 2003 Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 97 789-795.
145. Straub B, Muller M, Krause H, Schrader M, Goessl C, Heicappell R & Miller K 2001 Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers. Clinical Cancer Research 7 2340-2343.
146. Sunderland MC & Osborne CK 1991 Tamoxifen in premenopausal patients with metastatic breast cancer: a review. Journal of Clinical Oncology 9 1283-1297.
147. Szoke B, Horvath J, Halmos G, Rekasi Z, Groot K, Nagy A & Schally AV 1994 LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro. Peptides 15 359-366.
148. Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, Robert NJ, Budd GT, Paradelo JC, Natale RB et al. 1998 Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. Journal of Clinical Oncology 16 994-999.
149. Terasawa E 2003 Gonadotropin-releasing hormone II: is this neuropeptide important for mammalian reproduction? Endocrinology 144 3-4.
150. Terasawa E & Fernandez DL 2001 Neurobiological mechanisms of the onset of puberty in primates. Endocrine Reviews 22 111-151.
151. Thrush GR, Lark LR, Clinchy BC & Vitetta ES 1996 Immunotoxins: an update. Annual Review of Immunology 14 49-71.
152. Tobet SA, Bless EP & Schwarting GA 2001 Developmental aspect of the gonadotropin-releasing hormone system. Molecular and Cellular Endocrinology 185 173-184.
153. Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Fotheringham N, Campion M & Garnick MB 2002 A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Journal of Urology 167 1670-1674.
154. Uckun FM, Bellomy K, O'Neill K, Messinger Y, Johnson T & Chen CL 1999 Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. Journal of Pharmacology and Experimental Therapeutics 291 1301-1307.
155. Vasilyev VV, Lawson MA, Dipaolo D, Webster NJ & Mellon PL 2002 Different signaling pathways control acute induction versus long-term repression of LHbeta transcription by GnRH. Endocrinology 143 3414-3426.
156. Vickery BH 1986 Comparison of the potential for therapeutic utilities with gonadotropin-releasing hormone agonists and antagonists. Endocrine Reviews 7 115-124.
157. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M et al. 2002 Experience with indium-III and yttrium-90-labeled somatostatin analogs. Current Pharmaceutical Design 8 1781-1807.
158. de Voogt HJ, Suciu S, Sylvester R, Pavone-Macaluso M, Smith PH & de Pauw M 1989 Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. Journal of Urology 141 883-888.
159. Wang Y, Matsuo H, Kurachi O & Maruo T 2002 Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells. European Journal of Endocrinology 146 447-456.
160. Warner B, Worgul TJ, Drago J, Demers L, Dufau M, Max D & Santen RJ 1983 Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. Journal of Clinical Investigation 71 1842-1853.
161. Weinbauer GF & Nieschlag E 1992 LH-RH antagonists: state of the art and future perspectives. Recent Results in Cancer Research 124 113-136.
162. Wierman ME 1996 Gonadotropin-releasing hormone. In Reproductive Endocrinology, Surgery, and Technology, pp 666-681. Eds EY Adashi, JA Rock & Z Rosewaks. Philadelphia: Lippincott-Raven Publishers.
163. Wierman ME, Pawlowski JE, Allen MP, Xu M, Linseman DA & Nielsen-Preiss S 2004 Molecular mechanisms of gonadotropin-releasing hormone neuronal migration. Trends in Endocrinology and Metabolism 15 96-102.
164. Xu C, Xu XZ, Nunemaker CS & Moenter SM 2004 Dose-dependent switch in response of gonadotropin-releasing hormone (GnRH) neurons to GnRH mediated through the type I GnRH receptor. Endocrinology 145 728-735.
165. Yang WH, Wieczorck M, Allen MC & Nett TM 2003 Cytotoxic activity of gonadotropin-releasing hormone (GnRH)-pokeweed antiviral protein conjugates in cell lines expressing GnRH receptors. Endocrinology 144 1456-1463.
166. Yin H, Cheng KW, Hwa HL, Peng C, Auersperg N & Leung PC 1998 Expression of the messenger RNA for gonadotropin-releasing hormone and its receptor in human cancer cell lines. Life Sciences 62 2015-2023.